Literature DB >> 25308395

Proceed with caution: off-label ketamine treatment for major depressive disorder.

Dominic Sisti1, Andrea G Segal, Michael E Thase.   

Abstract

Ketamine offers a promising new option for the treatment of depression, but its increasing off-label use is ethically and clinically inappropriate at the moment.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25308395     DOI： 10.1007/s11920-014-0527-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


  14 in total

1.  The semantics of ketamine.

Authors:  S M Green; B Krauss
Journal:  Ann Emerg Med       Date:  2000-11       Impact factor: 5.721

2.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

3.  Journey through the K-hole: phenomenological aspects of ketamine use.

Authors:  L Muetzelfeldt; S K Kamboj; H Rees; J Taylor; C J A Morgan; H V Curran
Journal:  Drug Alcohol Depend       Date:  2008-03-19       Impact factor: 4.492

4.  A word to the wise about ketamine.

Authors:  Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2014-03       Impact factor: 18.112

5.  Ketamine--"dissociative agent" or hallucinogen?

Authors:  C E Reier
Journal:  N Engl J Med       Date:  1971-04-08       Impact factor: 91.245

6.  Decisional capacity in mental illness and substance use disorders: empirical database and policy implications.

Authors:  Dilip V Jeste; Elyn Saks
Journal:  Behav Sci Law       Date:  2006

7.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

8.  Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.

Authors:  Celia J A Morgan; Leslie Muetzelfeldt; H Valerie Curran
Journal:  Addiction       Date:  2009-11-17       Impact factor: 6.526

9.  Socioeconomic inequalities in depression: a meta-analysis.

Authors:  V Lorant; D Deliège; W Eaton; A Robert; P Philippot; M Ansseau
Journal:  Am J Epidemiol       Date:  2003-01-15       Impact factor: 4.897

10.  Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.

Authors:  Colleen K Loo; Natalie Katalinic; Joshua B B Garfield; Kirby Sainsbury; Dusan Hadzi-Pavlovic; Ross Mac-Pherson
Journal:  J Affect Disord       Date:  2012-08-02       Impact factor: 4.839
View more
  4 in total

1.  Brain Wellness "Spas"-Anticipating the Off-label Promotion of Psychedelics.

Authors:  Anna Wexler; Dominic Sisti
Journal:  JAMA Psychiatry       Date:  2022-08-01       Impact factor: 25.911

Review 2.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

Review 3.  Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.

Authors:  Sagar V Parikh; Daniela Lopez; Jennifer L Vande Voort; Jose Rico; Eric Achtyes; William Coryell; Andrew Goddard; Fernando Goes; John F Greden; Balwinder Singh; Adam Kaplin; Mark A Frye; Daniel Maixner; Brendon Watson; Karina Drake; Vijay Tarnal; Patricio Riva-Posse; William V Bobo
Journal:  Psychopharmacol Bull       Date:  2021-06-01

4.  Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015.

Authors:  Melvyn W B Zhang; Ying X Hong; Syeda F Husain; Keith M Harris; Roger C M Ho
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.